Inhibrx: 'Strong Buy' Maintained With Ozekibart Action Date On The Horizon And Study Win With INBRX-106

RegulatoryOzekibartINBRX-106Positive

AI Analysis

Summary

Inhibrx maintains 'Strong Buy' rating with an Ozekibart FDA action date approaching and a clinical study win reported for INBRX-106. No specific dates or outcomes are provided in the article.

Importance:5/10

Sentiment:

0.60

InhibrxOzekibartINBRX-106FDA action dateclinical trial

Related Companies

$HZNP

Read the original article

Published by Seeking Alpha Healthcare on September 14, 2026 1:46 PM

Read Original